Metastatic disease is the primary cause of death in breast cancer, the most common malignancy in Western women. Loss of E-cadherin is associated with tumor metastasis, as well as with invasive lobular carcinoma (ILC), which accounts for 10%-15% of all breast cancers. To study the role of E-cadherin in breast oncogenesis, we have introduced conditional E-cadherin mutations into a mouse tumor model based on epithelium-specific knockout of p53. Combined loss of E-cadherin and p53 resulted in accelerated development of invasive and metastatic mammary carcinomas, which show strong resemblance to human ILC. Moreover, loss of E-cadherin induced anoikis resistance and facilitated angiogenesis, thus promoting metastatic disease. Our results suggest that loss of E-cadherin contributes to both mammary tumor initiation and metastasis.
Introduction
Breast cancer is the most common malignancy among females in the Western world, affecting 12% of the female population and resulting in approximately half a million deaths annually (Althuis et al., 2005) . Invasive lobular carcinoma (ILC), which represents 10%-15% of all breast cancers, has a greater tendency for multifocality and bilaterality than other primary breast tumors (Arpino et al., 2004) . In its classical form, ILC consists of noncohesive cells that invade the parenchyma diffusely or arranged in trabecules without mass formation, often resulting in a falsenegative diagnosis using physical examination or mammography (Simpson et al., 2003) .
Breast cancer progression depends on the capacity to invade and to metastasize to distant sites. Loss of tumor cell adhesion is an important factor in this process. E-cadherin is a key component of adherens junctions, structures that play crucial roles in the maintenance of epithelial integrity (Perez-Moreno et al., 2003) . E-cadherin is a calcium-dependent cell adhesion molecule that mediates homophilic interactions and controls the formation of catenin-containing complexes that link E-cadherin to the actin and microtubule cytoskeleton (Hulsken et al., 1994; Takeichi, 1995; Perez-Moreno et al., 2003) . In cancer, loss of E-cadherin function through genetic or epigenetic mechanisms has been implicated in progression and metastasis of numerous malignancies (Vleminckx et al., 1991; Frixen et al., 1991; Oda et al., 1994; Cleton-Jansen et al., 1994; Berx et al., 1995; Graff et al., 1995; Yoshiura et al., 1995; Savagner et al., 1997; Perl et al., 1998; Batlle et al., 2000; Cano et al., 2000; Comijn et al., 2001; Fujita et al., 2003; Yang et al., 2004; Moody et al., 2005) . In breast cancer, the vast majority of ILCs have lost expression of E-cadherin, whereas most other subtypes have retained expression (Berx et al., 1995; Lehr et al., 2000; Korkola et al., 2003; Zhao et al., 2004) . While metastasis to lung, liver, and bone marrow is common in most types of human breast cancer, including ILC, gastrointestinal and peritoneal metastases are more frequent in ILC (Arpino et al., 2004) .
Although the expression and mutational status of E-cadherin may serve as a prognostic indicator in breast pathology, its contribution to tumor initiation, progression, and metastasis is
S I G N I F I C A N C E
Human invasive lobular carcinoma (ILC) is the second most common type of primary breast cancer. ILC is often difficult to diagnose and shows overall poor responses to conventional chemotherapy. This study shows that tissue-specific loss of E-cadherin and p53 in mice induces metastatic mammary carcinomas that resemble human ILC. The mouse model presented here provides a valuable tool to gain insights into the role of E-cadherin loss of function in mammary tumor initiation, progression, and metastasis and may ultimately contribute to the development of therapies for the treatment of lobular breast cancer. largely undefined. We therefore sought to study the consequences of somatic loss of E-cadherin in a mouse mammary tumor model based on epithelium-specific inactivation of p53. The data presented here show that combined loss of E-cadherin and p53 in mammary epithelial cells induces metastatic carcinomas that resemble human ILC.
Results

Conditional inactivation of E-cadherin alone does not induce tumor formation
To study the effects of E-cadherin loss on skin and mammary tumorigenesis, we employed conditional E-cadherin (Cdh1) gene inactivation using the Cre/loxP site-specific recombination system (Figures S1A-S1C in the Supplemental Data available with this article online) and crossed the resulting Cdh1 F conditional animals with K14cre transgenic mice ( Figure S1D ), which express the Cre recombinase in several epithelial tissues, including skin and mammary epithelium (Jonkers et al., 2001) . In line with the low and stochastic K14cre recombinase activity in mammary epithelium (Jonkers et al., 2001) , no abnormal ductal and alveolar development was observed in virgin, pregnant, or parous K14cre;Cdh1 F/F mice, and dams were able to nurse their litters (data not shown). K14cre-mediated loss of E-cadherin alone does not predispose to cancer, as none of the K14cre;Cdh1 F/F animals developed skin or mammary tumors. These findings are consistent with previous work showing that conditional inactivation of E-cadherin in either skin or mammary epithelium does not induce tumor formation (Boussadia et al., 2002; Young et al., 2003; Tinkle et al., 2004; Tunggal et al., 2005 Figure S3 , right panels). Tumors invaded subcutaneous fat and carnosus muscle in irregular strands and nest with polymorphic cells with dyskeratosis ( Figure S3 , right panels). Tumor cells expressed cytokeratin 14 (CK14) ( Figures S3C and S3D ) but lacked expression of CK1 and CK6 (data not shown), suggesting a basal origin. Occasionally, draining lymph nodes contained malignant epithelial cells, but distant metastases were absent. Figure 2 , left panels). Adenocarcinomas and solid carcinomas uniformly expressed CK8 and showed occasional sporadic expression of CK14 but lacked expression of vimentin ( Figure 2 , left panels; Table S1 ) and smooth muscle actin (SMA; data not shown). The third most common tumor type shows a carcinosarcoma phenotype, characterized by a metaplastic and biphasic histology comprised of epithelial and mesenchymal elements. These tumors show a heterogeneous expression pattern for CK8 and 14, often express vimentin, and mostly lack expression of E-cadherin (Table S1) Spindle-shaped tumor cells showed both expansive and invasive growth patterns, heterogeneously expressed CK8 and CK14, and mostly expressed vimentin, but lacked expression of E-cadherin and SMA (Table S1 and data not shown).
Loss of E-cadherin induces
Loss of E-cadherin contributes to mammary tumor initiation
Cre recombinase activity in mammary epithelium of K14cre transgenic females is relatively low, thus resulting in stochastic recombination of varying numbers of recombined alleles in individual Cre-expressing mammary epithelial cells (Jonkers et al., 2001) . The low activity of K14cre in mammary epithelium is exemplified by the mammary tumors from K14cre;Cdh1 F/+ ; Trp53 F/F females, which show-in addition to uniform recombination of both conditional Trp53 alleles-stochastic recombination of the single conditional Cdh1 allele ( Figure 1B) . Hence, the fact that the vast majority of primary mammary tumors from K14cre;Cdh1 F/F ;Trp53 F/F females have lost E-cadherin indicates selection for E-cadherin mutation during primary tumor formation, suggesting that E-cadherin loss of function contributes to tumor initiation. To verify this, we analyzed macroscopically tumor-free mammary glands from K14cre;Cdh1 F/F ; Trp53 F/F female animals for ductal morphology and E-cadherin expression. Immunohistochemical staining showed that E-cadherin expression was maintained in normal mammary epithelium of K14cre;Cdh1
F/F females. However, ducts could be found partly lined by or filled by atypical cells with luminal characteristics that lacked expression of E-cadherin and showed increased proliferation (Figure 3 ), suggesting that these cells represent an early, noninvasive (in situ) stage of tumor development. These findings indicate that loss of E-cadherin not only promotes mammary tumor progression and metastasis, but also contributes to tumor initiation in K14cre;Cdh1 F ;Trp53 F females.
Loss of E-cadherin induces metastatic mILC
To explore whether mILC mimics the metastatic pattern of human ILC, we performed a detailed histological survey into the metastatic spread of mILC. Table S1 ). Also, in a minority of animals dissociated or loosely clustered mILC cells were detected in organs such as lungs, liver, gastrointestinal and urogenital tract, and pancreas, or diffusely disseminated throughout the peritoneal cavity ( Figures 4E-4L ), indicating that mILC recapitulates the histopathology and tumor biology of human ILC. All mILC metastases expressed CK8 and showed a cellular morphology similar to that of the primary tumor ( Figure S1 ). Three K14cre;Cdh1
F/F females with a mixed carcinosarcoma/carcinoma tumor morphology showed dissemination of tumor cells to regional lymph nodes or lungs. Interestingly, one of these tumors had lost expression of E-cadherin (Table S1) .
To investigate the pattern of mILC metastasis in more detail, we isolated primary mammary tumor cells from K14cre;Trp53 (Figure 5A ). Metastases were detected in the peritoneal and thoracic cavity, contralateral mammary glands, and lungs ( Figures 5B-5E ). In addition, we detected osteolytic bone metastases in the vertebrae of the spinal column infiltrating the spinal cord ( Figure 5C ). These data show that the full metastatic spectrum of human ILC is recapitulated by the K14cre;Cdh1 tumors showed sensitivity to anoikis (p < 0.005; Figure 6C ), indicating that loss of E-cadherin facilitates survival of mammary tumor cells in the absence of cell-matrix interactions.
To determine whether loss of E-cadherin directly induces anchorage-independent cell survival, we tested whether 
;Trp53
D/D cells, suggesting that loss of E-cadherin plays a causal role in the acquisition of anoikis resistance. Figure 7C ).
Induction of angiogenesis in murine ILC
To verify whether mILC cells are a source of angiogenic factors, we harvested conditioned medium (CM) from Trp53 Figures 7D and 7E ). These data suggest that E-cadherin loss of function promotes the expression of proangiogenic factors that mediate tumor vascularization in mILC.
Discussion
Loss of E-cadherin has been extensively implicated in the progression and dissemination of human cancer Conacci-Sorrell et al., 2002; Cavallaro and Christofori, 2004) . Although a plethora of in vitro and clinical data suggest a strong involvement of E-cadherin mutation or silencing in lobular breast carcinoma, proof of a causal role for E-cadherin mutation in this malignancy is still lacking. Here, we present in vivo evidence that E-cadherin loss of function collaborates with p53 inactivation in the genesis, progression, and metastasis of mammary carcinoma. Furthermore, we impart a mouse model for human ILC, which represents up to 15% of invasive breast malignancies. E-cadherin loss promotes both primary tumor formation and metastatic disease Our model shows that E-cadherin acts as a tumor suppressor in the absence of p53 and that loss of E-cadherin and p53 effectively synergize in tumor formation. While combined inactivation of E-cadherin and p53 seems a prerequisite for mILC development, reduction in E-cadherin gene dosage does not provide a growth advantage in our model. Although we cannot exclude the possibility that E-cadherin has been silenced by either genetic or epigenetic mechanisms, selection for loss of the wildtype Cdh1 allele was not a common feature in tumors from K14cre;Cdh1 F/+ ;Trp53 F/F animals. This finding was unexpected, considering that E-cadherin loss of function in sporadic breast cancer frequently occurs by loss of heterozygosity (LOH) (Vos et al., 1997; Berx et al., 1998) or epigenetic silencing (Cano et al., 2000; Comijn et al., 2001; Hajra et al., 2002; Yang et al., 2004) . This difference may be explained by the fact that the efficiency of Cre-mediated deletion in K14cre-expressing mammary epithelial cells is approximately 60% per conditional allele (Jonkers et al., 2001) , whereas LOH occurs with a much lower efficiency of approximately 10 24 per cell generation per allele (Adams and Bradley, 2002 animals. K14cre-mediated conditional inactivation of E-cadherin alone in mammary epithelium does not predispose to tumors. This is probably due to the fact that E-cadherin loss in mouse mammary epithelium is not tolerated as a result of the rapid induction of apoptosis (Boussadia et al., 2002) . In concordance with this, we did not detect ductal structures lacking E-cadherin ;Trp53 F/F mammary tumors (left panels), whereas in K14cre;Cdh1 F/+ ;Trp53 F/F mILC (right panels) necrosis is absent. Bottom panels are a magnification of the upper panels. Scale bars, 1 mm (top panels) and 100 mm (bottom panels). B: Histopathology of K14cre;Cdh1 expression in K14cre;Cdh1 F/F females. We did, however, detect E-cadherin-negative epithelial in situ lesions in mammary glands from tumor-free K14cre;Cdh1 F/F ;Trp53 F/F females. Loss of E-cadherin in this setting appears to be an early, tumor-initiating event, which is most likely tolerated because the apoptotic signals that are induced upon E-cadherin inactivation cannot be executed in the absence of functional p53.
Several biological programs have to be deregulated in order to transform normal cells into malignant, metastatic tumor cells (Hanahan and Weinberg, 2000) . Loss of p53 results in loss of apoptotic responses and cell cycle control. This is, however, not sufficient to develop metastatic disease, as K14cre;Trp53 F/F and K14cre;Cdh1 F/+ ;Trp53 F/F females develop mammary carcinomas that only sporadically metastasize within the life span of the animals. Concomitant somatic loss of E-cadherin may provide key signals that promote tumor cell metastasis. First, mILC cells have acquired the potential to invade the surrounding stroma, which requires an increase in mobility and expression of the appropriate adhesion receptors. Second, the extremely dense and homogeneously distributed vascularization, as well as the capacity of mILC cells to function as a paracrine source of proangiogenic factors, indicate that somatic loss of E-cadherin may render mILC cells capable of inducing or enhancing angiogenesis. Finally, mILC cells have acquired anoikis resistance, which can facilitate tumor metastasis by permitting these cells to survive within the bloodstream and the lymphatic system and at distant organ sites. These findings imply that loss of Ecadherin invokes the capability to counteract the strong (p53-independent) proapoptotic signals that are induced upon loss of cell-matrix interactions. In summary, we conclude that, in our mILC model, loss of E-cadherin not only confers selective advantage during early stages of tumor development, but also promotes tumor progression and metastatic disease. Together, these findings support the notion that the signature of the primary tumor is a major determinant for clinical outcome ( Van 't Veer et al., 2002 ). E-cadherin may thus represent a prime example of a tumor suppressor that fits the same-gene hypothesis, which states that certain mutations that provide a selective advantage during tumor initiation can also foster an invasive and metastatic phenotype (Hanahan and Weinberg, 2000; Bernards and Weinberg, 2002 ).
E-cadherin loss induces a phenotypic change from expansive adenocarcinoma to invasive lobular carcinoma During mammary gland development, pluripotent cells can form both myoepithelial and luminal epithelial cell lineages. These cells, which express CK14, are thought to represent the mammary stem cells (Smalley and Ashworth, 2003; Althuis et al., 2005; Shackleton et al., 2006; Stingl et al., 2006) . All mammary carcinomas from the K14cre;Cdh1 F ;Trp53 F model showed similar epithelial phenotypes, characterized by expression of the luminal marker CK8, occasional expression of the myoepithelial marker CK14, and absence of SMA and vimentin. However, the majority of K14cre;Cdh1 
Trp53
F/F females developed invasive lobular instead of expansive carcinomas, indicating that the formation of mILC is a direct consequence of E-cadherin loss of function. E-cadherin is known to be important for both cell-cell adhesion and cell polarity (Drubin and Nelson, 1996) , and it is therefore conceivable that loss of these functions may impair the duct-forming capacity of mammary epithelial cells. While the cell of origin remains elusive, our data are compatible with the notion that ductal and lobular carcinomas may originate from a common (CK14-positive) progenitor cell (Wellings et al., 1975; Wellings, 1980) and raise the possibility that the lobular carcinoma phenotype may directly result from loss of E-cadherin-mediated cell adhesion.
E-cadherin loss does not induce classical epithelial-to-mesenchymal transition Numerous reports have shown that several transcription repressors of E-cadherin, such as SIP1, Snail, Slug, and Twist (Savagner et al., 1997; Batlle et al., 2000; Cano et al., 2000; Comijn et al., 2001; Hajra et al., 2002; Yang et al., 2004) can induce epithelial-to-mesenchymal transition (EMT) and subsequent metastasis. It has therefore been suggested that E-cadherin may be an important caretaker of the epithelial phenotype (Thiery, 2002) . Our data show that E-cadherin loss alone is not sufficient for EMT, since all mILCs from our K14cre;Cdh1 (Table 1) . While we cannot exclude the possibility that mILC cells transiently acquire mesenchymal properties during tumor invasion and dissemination, mILC might not require a complete EMT in order to metastasize. Conversely, the loss of E-cadherin-mediated cell adhesion and the spindleshape morphology of mILC cells could be regarded as a partial EMT. It will therefore be important to determine whether tumor cell metastasis induced by expression of EMT regulators such as SIP1, Snail, Slug, and Twist is solely mediated through repression of E-cadherin, or whether other transcriptional targets contribute to this process.
ILC in mice and men
Mouse ILC recapitulates several key features of human ILC, including cellular morphology, absence of Her2/Neu/Erbb2 expression, invasive growth patterns, and sites of metastasis. Nevertheless, there are also differences between mILC and human ILC. One important discrepancy is that, in contrast to human ILC, mILCs do not express estrogen receptors. This difference is in line with the fact that, whereas most human breast cancers are ER positive, most established mouse models develop ER-negative mammary tumors (Nandi et al., 1995) . Another potential difference between mILC and human ILC is the involvement of p53 mutations, which are thought to occur in a minority (4%-25%) of human ILC cases (Marchetti et al., 1993; Rosen et al., 1995; Soslow et al., 2000; Coradini et al., 2002; Arpino et al., 2004) . Most analyses, however, have been performed using immunohistochemical detection of mutant p53 protein, leaving the possibility of functional p53 loss through alternative mechanisms. Supporting this are recent studies showing that 30%-40% of human lobular carcinomas have lost the TP53 locus on chromosome 17p13 (Mohsin et al., 2005; Stange et al., 2006) . In summary, we have shown that somatic loss of E-cadherin and p53 in mice induces mammary tumors with histological characteristics similar to human ILC, a malignancy for which no mouse model was available until now. Concomitant loss of E-cadherin and p53 orchestrates a complex tactic that impacts on multiple aspects of oncogenesis, including tumor initiation, angiogenesis, tumor cell survival, invasion, and metastasis. Our mILC model may prove a valuable tool for the identification of the molecular consequences of E-cadherin inactivation during mammary tumorigenesis and may facilitate designing and testing of treatment modalities for human ILC.
Experimental procedures
Construction of targeting vectors
To target the Cdh1 locus, we isolated two clones from a mouse 129/Sv PAC library (RPCI-21, BACPAC Resources) using probes directed against exons 7 and 8 of Cdh1. From the PAC clones, 12 kb and 7.0 kb BamHI fragments were isolated using probes against Cdh1 exons 4 and 14, respectively. The 5 0 targeting construct was generated from the 12 kb BamHI fragment by inserting a loxP-PGKneo-loxP cassette into a unique AvrII site present in Cdh1 intron 3. For the 3 0 targeting construct, we used the 7 kb BamHI fragment to insert a loxP-PGKhygro-loxP cassette into a unique EcoRV site present in Cdh1 intron 15.
Generation of Cdh1
F/+ conditional mice A sequential gene targeting approach was undertaken to introduce single loxP sites in introns 3 and 15 of murine Cdh1 (Figures S1A-S1C ). The 5 0 and 3 0 targeting constructs were released from the pGEM5 vector by NotI digestion. The 5 0 targeting construct was electroporated into 129/Ola-derived E14-IB10 ES cells (Robanus-Maandag et al., 1998) , and correctly targeted neomycin-resistant ES cells were identified by Southern blot analysis. One of these clones was subsequently electroporated with the 3 0 targeting construct and subjected to hygromycin selection. Following identification of positive clones by Southern blot analysis, removal of the neomycin and hygromycin selection markers was achieved by transient Cre expression as described (Jonkers et al., 2001 ). Clones were analyzed by PCR using primers P1 (5 0 -ACATGTTTGTATCGATCTCAG-3 0 ) and P2 (5 0 -CCATACACTGATAAT GTCAGA-3 0 ) to detect deletion of the neomycin cassette and primers P3 (5 0 -TCAATCTCAGAGCCCCACCTA-3 0 ) and P4 (5 0 -CCTGCCATGATTGTCA TGGAC-3 0 ) to detect deletion of the hygromycin cassette, thus leaving behind single loxP sites in introns 3 and 15, respectively. Next, we confirmed dual targeting in cis by Southern blot analysis of SacI-digested DNA from positive ES cell clones with a Chd1 exon 3 probe. The resulting Cdh1 F/+ ES cells were injected into C56Bl/6 blastocysts, and chimeras were crossed with FVB/N mice to produce heterozygous offspring. The resulting Cdh1 F/+ heterozygous and Cdh1 F/F homozygous mice were viable and fertile and showed a normal life span, indicating that the Cdh1 F allele is fully functional. To test whether tissue-specific deletion of Cdh1 exons 4 to 15 leads to functional inactivation of E-cadherin, we crossed Cdh1 F/F homozygotes with K14cre transgenic mice, which express the Cre recombinase in several epithelial tissues, including skin and mammary epithelium (Jonkers et al., 2001 ). The resulting K14cre;Cdh1 F/F animals showed stochastic loss of E-cadherin protein expression in skin epithelium, demonstrating that deletion of exons 4 to 15 of E-cadherin results in a functional null allele ( Figure S1D ). In contrast to the phenotypically normal K14cre;Cdh1 F/+ animals, K14cre;Cdh1 F/F mice showed developmental defects in skin epithelium, resulting in disturbed hair follicle development, epidermal hyperplasia with frequent inflammation, progressive hair loss, and abnormal sebaceous gland development (data not shown). All animal experiments were approved by the Animal Ethical Committee and conducted in compliance with the Netherlands Cancer Institute and Dutch Animal Welfare guidelines.
DNA analysis
Genomic DNA was isolated from tissue by proteinase K lysis and organic extraction with phenol-chloroform. We performed Southern blot analysis using 10 mg of gDNA, digested with BglII or ScaI, to determine the status of the Trp53 and Cdh1, respectively. Blotting and hybridization was performed as described (Jonkers et al., 2001) . The Trp53 probe has been described (Jonkers et al., 2001 ). The Cdh1 probe was generated by PCR amplification of a 250 bp fragment of exon 16 using primers 5 0 -TTGAAGGATGCACC GGCCGGC-3 0 and 5 0 -GGCGTGGTGGTGCCGGTGATG-3 0 . Probes were radiolabeled by PCR.
Genotyping of mutant mice Detection of the K14cre, Trp53 F , and Trp53 D alleles was done as described previously (Jonkers et al., 2001) . We detected the Cdh1 F allele by PCR amplification of the loxP site in intron 15, using primer pair P1 and P2, yielding 270 bp and 330 bp for the wild-type and floxed alleles, respectively. The deleted allele, Cdh1 D , was detected by PCR using primers P1 and P4, yielding a product of 320 bp. PCR conditions were as described (Jonkers et al., 2001 ).
Antibodies
The following antibodies were used: (FITC-conjugated) mouse anti-Ecadherin (1:300; BD Biosciences), mouse anti-E-cadherin (1:1000; Zymed), rat anti-E-cadherin (DECMA-1; 1:2000) (Sigma), mouse anti-b-catenin (1:150; BD Biosciences), rat anti-cytokeratin (CK) 8 (Troma-1; 1:125; DSHB products), mouse anti-CK8 (CAM5.2; 1:400; BD Biosciences), rabbit anti-CK14 (1:10,000; BabCo), mouse anti-CK14 (1:200; Neomarkers), guinea pig anti-vimentin (1:400; RDI), mouse anti-vimentin (3B4; 1:400), mouse anti-SMA (1:10; Zymed), rabbit anti-SMA (1:350; Lab Vision), and goat anti-CD31 (1:200; Santa Cruz). Secondary antibodies were as follows: biotin-conjugated anti-mouse, anti-rat and anti-rabbit antibodies (DAKO), biotin-conjugated anti-guinea pig (Jackson ImmunoResearch), Alexa 568-conjugated anti-mouse (Molecular Probes), and RPE-conjugated anti-rat (Southern Biotechnology Associates).
Histological analysis
Tissues were isolated and fixed in 4% formaldehyde for 48 hr. Tissues were dehydrated, cut into 4 mm sections, and stained with hematoxylin and eosin. For single staining, fixed sections were rehydrated and incubated with primary antibodies. Endogenous peroxidases were blocked with 3% H 2 O 2 and stained with biotin-conjugated secondary antibodies, followed by incubation with HRP-conjugated streptavidin-biotin complex (DAKO). Substrate was developed with either AEC or DAB (DAKO). For immunofluorescence, cells were grown on coverslips and fixed in ice-cold methanol. Cells were permeabilized using 0.5% Triton/PBS and subsequently incubated with primary antibodies. Then, cells were incubated with fluorochrome-conjugated secondary antibodies. DNA was stained with ToPro-3 (Molecular Probes), and cells were analyzed by confocal laser microscopy.
Cell culture
For the isolation of primary tumor cells, 50-100 mm 3 tumor sample was finely chopped using a McIlwain tissue chopper (The Mickle Laboratory Engineering Co.) and digested for 1 hr at 37 C in serum-free DMEM-F12 medium (Invitrogen Life Technologies) containing 0.1 mg/ml porcine pancreatic trypsin (Difco) and 0.2 mg/ml collagenase A (Roche). Cells were washed and fibroblasts were allowed to adhere for 1 hr at 37 C. Nonadherent epithelial cells were removed and cultured in DMEM-F12 medium containing 10% fetal bovine serum (FBS; ICN), 100 IU/ml penicillin, 100 mg/ml streptomycin, 5 ng/ml insulin, 5 ng/ml epidermal growth factor (EGF) (all Invitrogen Life Technologies), and 5 ng/ml cholera toxin (Sigma). 293T cells were cultured in Iscove's medium (Invitrogen Life Technologies) containing 10% FBS, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Retroviral production and transduction of cells
The mouse E-cadherin cDNA (a kind gift from Dr. G. Christofori, University of Basel, Switzerland) was subcloned into pBABE-puro and pMSCV-blast retroviral vectors. For production of ecotropic retroviruses, 10 6 Phoenix packaging cells were seeded onto 10 cm petri dishes and transiently transfected after 24 hr with either pBABE-Cdh1 or pMSCV-Cdh1 using Fugene-6 transfection reagent (Roche). Supernatant containing viral particles was harvested after 72 hr and passed through a 45 mm filter. Retroviral infection of tumor cells was performed three times for 4 hr in the presence of 4 mg/ml polybrene (Sigma). Lentiviral particles were produced by seeding 10 6 293T cells onto a 10 cm petri dish and transient transfection after 24 hr with third-generation packaging constructs (Dull et al., 1998 ) and a luciferase-encoding transfer vector (LV-luc). The LV-luc vector was constructed by replacing the GFP coding region from pCSCG (Miyoshi et al., 1998) with the luciferase coding sequence from pNF-kB-Luc (Clontech). Supernatant containing lentiviral particles was harvested after 48 and 72 hr, passed through a 45 mm filter, and concentrated by centrifugation at 20,000 rpm for 2.5 hr. Virus particles were dissolved in serum-free DMEM-F12 (Invitrogen), snap frozen in liquid nitrogen, and stored at 280 C. Tumor cells were infected with LV-luc for 16 hr in the presence of 4 mg/ml polybrene.
Orthotopic transplantations and bioluminescence imaging
Three-week-old Rag2 2/2 ;IL2Rgc 2/2 BALB/c females (Gimeno et al., 2004 ) were anesthetized by intraperitoneal (i.p.) injection of a mixture containing 25 ml hypnorm (Janssen Pharmaceutica), 25 ml dormicum (Roche), and 50 ml water. The fourth mammary gland was exposed, and endogenous mammary epithelial tissue was removed. Next, approximately 10,000 luciferase-transduced tumor cells were injected in the cleared fat pad using a Hamilton syringe, after which the animals were sutured. After a recovery period of 2 weeks, mice were anesthetized with isofluorane (Janssen Pharmaceutica), injected i.p. with 225 mg/g body weight n-luciferin (potassium salt; Xenogen Corp.), and imaged on a IVIS-100 bioluminescence imager (Xenogen Corp.).
Anoikis assay
Cells were plated at a density of 75,000 cells per well in a 6-well ultra-low cluster polystyrene culture dish (Corning). After the indicated time interval, cells were harvested and incubated at 37 C with 0.25% trypsin (Invitrogen) for 1 min to prevent cell aggregation. FITC-conjugated Annexin-V (IQ Products) and ToPro-3 (Molecular Probes), were added and Annexin-V-positive apoptotic cells were analyzed by FACS as described (Derksen et al., 2003) . Statistical significance was calculated using the Student's t test.
Sprouting assay
Bovine microvascular endothelial cells (BCEs), kindly provided by Dr. M. Furie (State University of New York, Stony Brook, NY), were cultured on gelatin-coated flasks in DMEM supplemented with 10% FBS (Perbio Science), 50 IU/ml penicillin, 50 ng/ml streptomycin, and 30 mg/ml endothelial cell growth supplement (ECGS; BD Biosciences). BCEs were mixed with gelatin-coated cytodex-3 beads (Sigma) at a concentration of 100 cells per bead and cultured for 72 hr in BCE medium supplemented with 25% serum-free conditioned medium from Trp53 D/D or Cdh1
;Trp53 D/D mILC cells. The beads were subsequently resuspended at a concentration of 25 beads per 100 ml in a collagen gel mixture consisting of 2.4 mg/ml vitrogen-100 (Collagen, Fremont, CA), 13 a-MEM (Life Technologies), and 1.2 mg/ml sodium bicarbonate (Merck). Solidified gel was overlaid with BCE medium supplemented with serum-free 25% conditioned medium from the indicated cell lines, 20 ng/ml bFGF (Reliatech), or DMEM as control. Photographs were taken after 48 hr. Five concentric rings were projected over the photographs, and the number of intersections of rings and sprouting endothelial cells was determined and used as a measure of in vitro tube formation. Statistical analyses were done using the Student's t test.
Supplemental data
The Supplemental Data include three supplemental figures and one supplemental table and can be found with this article online at http://www. cancercell.org/cgi/content/full/10/5/437/DC1/.
